Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117422) titled 'Sintilimab Plus Systemic Chemotherapy With or Without Intraperitoneal Nab-Paclitaxel for Treatment-Naive HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Phase III Randomized Controlled Trial' on Jan. 23.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Gastric or gastro-esophageal junction adenocarcinoma
Intervention:
SOX + Sintilimab Group (Group A):Subjects will receive 6 cycles of systemic therapy with SOX + Sintilimab, followed by assessment for conversion surgery, and subsequent maint...